Physician profile
Lawrence E Schmitz
NPI 1104886761
$3,354.56
in general payments reported to CMS, 2019-2025
31 companies · $439 in 2025
The $439 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $241 · 2021: $865 · 2022: $569 · 2023: $625 · 2024: $168 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.46 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,095.84 | 2019-2023 | Lo Loestrin Fe |
| Sumitomo Pharma America, INC. | $266.11 | 2023-2025 | Myfembree, Gemtesa |
| Mayne Pharma Commercial LLC | $257.63 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $189.11 | 2019-2024 | |
| Pfizer INC. | $185.89 | 2019-2023 | |
| Exeltis, USA INC. | $180.12 | 2021-2024 | Slynd |
| Allergan, INC. | $176.04 | 2019 | |
| Organon LLC | $94.18 | 2021-2025 | Nexplanon, Jada System |
| Gynesonics, INC. | $93.89 | 2021 | |
| Kvk-Tech, INC. | $90.40 | 2025 | |
| Hologic Sales and Service, LLC | $86.38 | 2020-2023 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Millicent US INC | $70.15 | 2025 | Femlyv, Intrarosa |
| Medtronic, INC. | $64.24 | 2021-2023 | Ligasure, V-Loc 180 |
| Myovant Sciences INC. | $62.95 | 2021-2022 | |
| Biogen, INC. | $60.39 | 2025 | Zurzuvae |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $38.33 | 2022 | |
| Baxter Healthcare | $36.31 | 2022 | |
| Intuitive Surgical, INC. | $35.45 | 2024 | |
| Minerva Surgical, INC | $35.36 | 2023 | |
| Lilly USA, LLC | $34.32 | 2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $34.32 | 2019-2021 | |
| Therapeuticsmd, INC. | $27.38 | 2019-2022 | |
| Coopersurgical, INC. | $20.35 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.50 | 2022 | |
| Evofem Biosciences, INC. | $18.26 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.17 | 2021 | |
| Horizon Therapeutics Plc | $15.65 | 2020 | |
| Mylan Pharmaceuticals INC. | $13.49 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.47 | 2019 | |
| Channel Medsystems, INC. | $11.53 | 2024 | |
| Sage Therapeutics, LLC | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Schmitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.